Lupin Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Lupin kazanç ve gelirin sırasıyla yıllık 19.2% ve 9% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 18.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 18.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

19.2%

Kazanç büyüme oranı

18.7%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	18.3%
Gelir büyüme oranı	9.0%
Gelecekteki özkaynak getirisi	18.9%
Analist kapsamı	Good
Son güncelleme	27 Oct 2024

Gelecekteki son büyüme güncellemeleri

Lupin Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 09

Lupin Limited (NSE:LUPIN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Jul 13

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

May 09

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 10

Recent updates

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

Sep 17

Lupin Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 09

Unpleasant Surprises Could Be In Store For Lupin Limited's (NSE:LUPIN) Shares

Aug 01

Lupin Limited (NSE:LUPIN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Jul 13

Lupin's (NSE:LUPIN) Dividend Will Be Increased To ₹8.00

Jul 12

These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely

Jun 15

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

May 09

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 10

Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk

Jan 19

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Nov 10

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Jun 23

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Mar 24

Lupin's (NSE:LUPIN) Dividend Is Being Reduced To ₹4.00

Jul 08

Kazanç ve Gelir Büyüme Tahminleri

NSEI:LUPIN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2027	263,091	37,815	36,244	N/A	22
3/31/2026	248,312	35,655	30,176	N/A	31
3/31/2025	221,427	27,732	20,733	N/A	33
6/30/2024	207,971	22,635	N/A	N/A	N/A
3/31/2024	200,108	19,145	27,195	36,484	N/A
12/31/2023	194,801	17,910	N/A	N/A	N/A
9/30/2023	186,049	13,314	18,582	34,087	N/A
6/30/2023	177,119	9,714	N/A	N/A	N/A
3/31/2023	166,417	4,301	3,976	18,972	N/A
12/31/2022	160,946	-3,239	N/A	N/A	N/A
9/30/2022	159,333	682	-19,299	-9,456	N/A
6/30/2022	158,791	-21,596	N/A	N/A	N/A
3/31/2022	164,055	-15,280	-5,378	3,673	N/A
12/31/2021	163,052	-5,497	N/A	N/A	N/A
9/30/2021	161,616	-6,570	22,007	29,207	N/A
6/30/2021	159,053	16,521	N/A	N/A	N/A
3/31/2021	151,630	12,165	11,441	18,218	N/A
12/31/2020	152,260	11,458	N/A	N/A	N/A
9/30/2020	149,777	-1,609	-4,671	523	N/A
6/30/2020	150,249	-5,572	N/A	N/A	N/A
3/31/2020	153,748	-3,995	7,957	14,688	N/A
12/31/2019	174,693	-4,428	N/A	N/A	N/A
9/30/2019	176,892	3,138	21,219	29,124	N/A
6/30/2019	172,806	7,068	N/A	N/A	N/A
3/31/2019	146,646	5,121	6,806	16,660	N/A
12/31/2018	163,114	-4,665	N/A	N/A	N/A
9/30/2018	157,822	-931	N/A	N/A	N/A
6/30/2018	157,829	960	N/A	N/A	N/A
3/31/2018	157,765	2,513	N/A	17,512	N/A
12/31/2017	159,233	14,150	N/A	N/A	N/A
9/30/2017	164,306	18,264	N/A	N/A	N/A
6/30/2017	167,693	20,336	N/A	N/A	N/A
3/31/2017	173,674	25,575	N/A	41,135	N/A
12/31/2016	173,910	29,351	N/A	N/A	N/A
9/30/2016	164,558	28,265	N/A	N/A	N/A
6/30/2016	154,918	25,841	N/A	N/A	N/A
3/31/2016	141,316	22,607	N/A	-3,824	N/A
12/31/2015	131,055	20,106	N/A	N/A	N/A
9/30/2015	127,273	20,823	N/A	N/A	N/A
6/30/2015	125,794	23,035	N/A	N/A	N/A
3/31/2015	127,700	24,032	N/A	27,331	N/A
12/31/2014	128,124	24,092	N/A	N/A	N/A
9/30/2014	126,567	22,839	N/A	N/A	N/A
6/30/2014	121,512	20,601	N/A	N/A	N/A
3/31/2014	112,866	18,364	N/A	20,039	N/A
12/31/2013	107,519	16,915	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: LUPIN 'nin tahmini kazanç büyümesi (yıllık 19.2% ) tasarruf oranının ( 6.7% ) üzerindedir.

Kazançlar ve Piyasa: LUPIN şirketinin kazançlarının (yıllık 19.2% ) Indian pazarından (yıllık 18.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: LUPIN şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: LUPIN şirketinin gelirinin (yıllık 9% ) Indian pazarından (yıllık 10.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: LUPIN şirketinin gelirinin (yıllık 9% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: LUPIN 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 18.9 %).

Lupin Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 12% to ₹1,835

Lupin Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Lupin Limited (NSE:LUPIN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Price target increased by 12% to ₹1,355

Recent updates

Lupin Limited to Report Q2, 2025 Results on Nov 07, 2024

Lupin Limited Announces its Wholly Owned Subsidiary Lupin Management, Inc., USA Appoints Claus Jepsen as President, Global Specialty

Lupin Launches First Generic of Pred Forte® in the United States

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

Price target increased by 12% to ₹1,835

Lupin Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Lupin Limited Announces Change of Company Secretary and Compliance Officer

Lupin Limited Approves Dividend for Year Ended March 31, 2024

Unpleasant Surprises Could Be In Store For Lupin Limited's (NSE:LUPIN) Shares

Lupin Limited to Report Q1, 2025 Results on Aug 06, 2024

Lupin Limited (NSE:LUPIN) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Lupin's (NSE:LUPIN) Dividend Will Be Increased To ₹8.00

Full year 2024 earnings: EPS misses analyst expectations

Dividend increased to ₹8.00

Lupin Limited, Annual General Meeting, Aug 02, 2024

These 4 Measures Indicate That Lupin (NSE:LUPIN) Is Using Debt Safely

Lupin Limited Announces Board Appointments

Analysts Are Updating Their Lupin Limited (NSE:LUPIN) Estimates After Its Annual Results

New minor risk - Dividend sustainability

With EPS Growth And More, Lupin (NSE:LUPIN) Makes An Interesting Case

Full year 2024 earnings: EPS misses analyst expectations

Lupin Limited to Report Q4, 2024 Results on May 06, 2024

Investor Optimism Abounds Lupin Limited (NSE:LUPIN) But Growth Is Lacking

Lupin Limited Announces Change in Management

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.075% in the United States

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Price target increased by 12% to ₹1,355

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.075%

Insufficient new directors

Lupin Limited to Report Q3, 2024 Results on Feb 07, 2024

Lupin Receives Approval from U.S. FDA for Febuxostat Tablets

Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.07% in the United States

Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.2%

Lupin Limited Receives Tentative Approval from U.S. FDA for Canagliflozin Tablets

Lupin Limited Launches First Fixed-Dose Triple Combination Drug, Vilfuro-G® for COPD Management in India

Lupin Limited Receives Tentative Approval from U.S. FDA for Dapagliflozin Tablets

Price target increased by 8.2% to ₹1,067

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited to Report Q2, 2024 Results on Nov 08, 2023

Lupin Limited Receives Tentative Approval from U.S. FDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution

Lupin Limited (BSE:500257) completed the acquisition of Ondero and Ondero - Met from Boehringer Ingelheim International GmbH.

Price target increased by 15% to ₹878

Lupin Limited Approves Dividend for the Year Ended March 31, 2023

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Lupin Limited Receives Tentative Approval from U.S. Fda for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility

Upcoming dividend of ₹4.00 per share at 0.4% yield

Lupin Limited, Annual General Meeting, Aug 03, 2023

Lupin Limited Receives Approval from U.S. Fda for Cyanocobalamin Nasal Spray

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Lupin Limited Launches Thiamine Hydrochloride Injection USP in the United States

Lupin Launches Darunavir Tablets in the United States

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Third quarter 2023 earnings: Revenues in line with analyst expectations

Lupin Receives Approval from US FDA for Glycopyrrolate Injection, USP

Lupin Limited Receives Tentative Approval from U.S. FDA for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets

Lupin Limited to Report Q3, 2023 Results on Feb 09, 2023

Lupin Limited Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients

Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets

Lupin and Exeltis Announce Reimbursement Approval of NaMuscla in Spain for the Symptomatic Treatment of Myotonia in Adults with Non-Dystrophic Myotonic Disorders

Lupin Receives Approval from U.S. FDA for Fesoterodine Fumarate Extended-Release Tablets

Lupin Limited Launches Novel Fixed-Dose Triple Drug Combination Difizma® Dpi to Treat Inadequately Controlled Asthma